Bio-Rad Laboratories Return on Tangible Equity 2010-2024 | BIO
Current and historical return on tangible equity values for Bio-Rad Laboratories (BIO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Bio-Rad Laboratories Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-09-30 | $-0.78B | $6.77B | -10.67% |
| 2024-06-30 | $-1.33B | $6.06B | -17.62% |
| 2024-03-31 | $-0.32B | $8.33B | -4.06% |
| 2023-12-31 | $-0.64B | $8.01B | -7.86% |
| 2023-09-30 | $-0.16B | $7.70B | -1.91% |
| 2023-06-30 | $-0.43B | $7.71B | -5.13% |
| 2023-03-31 | $-0.19B | $9.03B | -2.25% |
| 2022-12-31 | $-3.63B | $8.88B | -42.01% |
| 2022-09-30 | $-6.02B | $7.73B | -62.16% |
| 2022-06-30 | $-1.93B | $8.34B | -16.82% |
| 2022-03-31 | $-0.09B | $9.59B | -0.74% |
| 2021-12-31 | $4.25B | $13.08B | 34.59% |
| 2021-09-30 | $6.67B | $14.86B | 58.61% |
| 2021-06-30 | $4.05B | $11.12B | 41.61% |
| 2021-03-31 | $4.11B | $10.13B | 47.33% |
| 2020-12-31 | $3.81B | $9.39B | 50.09% |
| 2020-09-30 | $3.52B | $8.33B | 53.30% |
| 2020-06-30 | $1.95B | $6.85B | 34.13% |
| 2020-03-31 | $1.58B | $5.89B | 29.96% |
| 2019-12-31 | $1.76B | $5.35B | 35.73% |
| 2019-09-30 | $0.38B | $4.72B | 8.35% |
| 2019-06-30 | $0.90B | $5.12B | 20.62% |
| 2019-03-31 | $0.57B | $4.49B | 13.98% |
| 2018-12-31 | $0.37B | $3.67B | 9.30% |
| 2018-09-30 | $1.28B | $4.25B | 35.75% |
| 2018-06-30 | $1.03B | $3.98B | 33.80% |
| 2018-03-31 | $0.77B | $3.81B | 29.78% |
| 2017-12-31 | $0.12B | $2.25B | 5.75% |
| 2017-09-30 | $0.02B | $2.15B | 0.78% |
| 2017-06-30 | $0.01B | $2.10B | 0.60% |
| 2017-03-31 | $0.03B | $2.00B | 1.28% |
| 2016-12-31 | $0.03B | $1.94B | 1.32% |
| 2016-09-30 | $0.09B | $1.98B | 5.06% |
| 2016-06-30 | $0.09B | $1.88B | 5.20% |
| 2016-03-31 | $0.10B | $1.79B | 5.99% |
| 2015-12-31 | $0.11B | $1.78B | 6.67% |
| 2015-09-30 | $0.10B | $1.70B | 6.59% |
| 2015-06-30 | $0.10B | $1.61B | 6.60% |
| 2015-03-31 | $0.10B | $1.45B | 7.10% |
| 2014-12-31 | $0.09B | $1.43B | 6.32% |
| 2014-09-30 | $0.08B | $1.39B | 5.71% |
| 2014-06-30 | $0.06B | $1.42B | 4.42% |
| 2014-03-31 | $0.07B | $1.46B | 4.74% |
| 2013-12-31 | $0.08B | $1.40B | 5.92% |
| 2013-09-30 | $0.09B | $1.33B | 7.10% |
| 2013-06-30 | $0.14B | $1.29B | 11.35% |
| 2013-03-31 | $0.15B | $1.24B | 12.77% |
| 2012-12-31 | $0.17B | $1.26B | 14.09% |
| 2012-09-30 | $0.18B | $1.18B | 16.40% |
| 2012-06-30 | $0.19B | $1.15B | 16.80% |
| 2012-03-31 | $0.18B | $1.10B | 16.12% |
| 2011-12-31 | $0.18B | $1.02B | 16.52% |
| 2011-09-30 | $0.19B | $1.14B | 17.43% |
| 2011-06-30 | $0.19B | $1.13B | 18.51% |
| 2011-03-31 | $0.18B | $1.05B | 20.10% |
| 2010-12-31 | $0.19B | $0.97B | 22.09% |
| 2010-09-30 | $0.16B | $0.87B | 19.86% |
| 2010-06-30 | $0.15B | $0.77B | 20.30% |
| 2010-03-31 | $0.15B | $0.75B | 21.61% |
| 2009-12-31 | $0.15B | $0.75B | 22.62% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $9.168B | $2.671B |
| Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels outside the United States through subsidiaries which focus on sales, customer service and product distribution. The company operates through two reportable segments - Life Science segment which designs, manufactures, markets and services reagents, apparatus and instruments utilized for biological research. Clinical Diagnostics - This business markets and distributes products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians office laboratories, transfusion laboratories as well as insurance and forensic testing laboratories. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $198.127B | 25.27 |
| Stryker (SYK) | United States | $138.991B | 31.32 |
| Boston Scientific (BSX) | United States | $131.097B | 37.69 |
| EssilorLuxottica (ESLOY) | France | $109.895B | 0.00 |
| Medtronic (MDT) | Ireland | $103.904B | 15.43 |
| Haleon (HLN) | United Kingdom | $43.864B | 28.50 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.859B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $36.052B | 18.70 |
| ResMed (RMD) | United States | $34.830B | 28.62 |
| Terumo (TRUMY) | Japan | $28.875B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $23.602B | 18.07 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.325B | 13.58 |
| Insulet (PODD) | United States | $18.698B | 74.46 |
| Baxter (BAX) | United States | $15.062B | 9.80 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.781B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.800B | 39.43 |
| Demant (WILYY) | Denmark | $7.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.208B | 14.42 |
| Prestige Consumer Healthcare (PBH) | United States | $3.889B | 19.34 |
| ICU Medical (ICUI) | United States | $3.840B | 36.56 |
| Haemonetics (HAE) | United States | $3.789B | 18.49 |
| Perrigo (PRGO) | Ireland | $3.513B | 10.34 |
| Envista Holdings (NVST) | United States | $3.218B | 23.97 |
| QuidelOrtho (QDEL) | United States | $3.016B | 19.41 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.864B | 18.36 |
| Neogen (NEOG) | United States | $2.609B | 30.10 |
| LeMaitre Vascular (LMAT) | United States | $2.071B | 50.34 |
| Green Thumb Industries (GTBIF) | United States | $1.678B | 29.37 |
| AtriCure (ATRC) | United States | $1.498B | 0.00 |
| InMode (INMD) | Israel | $1.434B | 8.63 |
| AdaptHealth (AHCO) | United States | $1.383B | 9.88 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.356B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.271B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.968B | 0.00 |
| Owens & Minor (OMI) | United States | $0.965B | 7.54 |
| CeriBell (CBLL) | United States | $0.964B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.879B | 15.49 |
| Evolus (EOLS) | United States | $0.690B | 0.00 |
| Omeros (OMER) | United States | $0.597B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.594B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.584B | 25.75 |
| Surmodics (SRDX) | United States | $0.568B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.452B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.439B | 0.00 |
| Quanterix (QTRX) | United States | $0.403B | 0.00 |
| ZimVie (ZIMV) | United States | $0.375B | 31.63 |
| Biote (BTMD) | United States | $0.331B | 7.26 |
| Valneva SE (VALN) | France | $0.324B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.311B | 29.56 |
| Canopy Growth (CGC) | Canada | $0.308B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.294B | 0.00 |
| Cerus (CERS) | United States | $0.293B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.272B | 18.20 |
| Zynex (ZYXI) | United States | $0.263B | 55.00 |
| High Tide (HITI) | Canada | $0.242B | 100.33 |
| Aurora Cannabis (ACB) | Canada | $0.234B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.207B | 14.29 |
| Sanuwave Health (SNWV) | United States | $0.201B | 2.82 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.197B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.190B | 0.00 |
| Brainsway (BWAY) | Israel | $0.174B | 92.40 |
| FitLife Brands (FTLF) | United States | $0.145B | 18.17 |
| Jin Medical (ZJYL) | China | $0.133B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.124B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.107B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.81 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.096B | 0.00 |
| Veru (VERU) | United States | $0.095B | 0.00 |
| Exagen (XGN) | United States | $0.091B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.067B | 34.67 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.056B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.051B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.048B | 0.00 |
| Safety Shot (SHOT) | United States | $0.044B | 0.00 |
| ImmuCell (ICCC) | United States | $0.039B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.74 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |